U.S. Stock Movement | U.S. clinical-stage biopharmaceutical company Retention Pharmaceuticals (RTSN.US) debuts on the U.S. stock market, with its share price falling more than 10% after the opening.

Zhito Finance APP has learned that on Friday, Retension Pharmaceuticals (RTSN.US) listed on the U.S. stock market. As of press time, the stock has fallen more than 10%, at $10.77. The IPO price was $12. Retension Pharmaceuticals is a U.S. clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a next-generation phosphodiesterase 5 (PDE5) inhibitor, mainly targeting patients with inadequately controlled blood pressure and resistant hypertension, and is currently conducting a Phase IIb clinical trial. The drug helps dilate blood vessels and lower blood pressure by enhancing nitric oxide signaling in blood vessels, and its exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).